$37.50
Manufacturer: Poland
Description
Supplement to standard treatment with beta-blockers to reduce the risk of cardiovascular disease-related morbidity and mortality in stable patients with left ventricular dysfunction (left ventricular ejection fraction ≤ 40%) and clinical signs of heart failure after a recent myocardial infarction. Supplement to standard optimal therapy to reduce the risk of cardiovascular disease-related morbidity and mortality in adult patients with NYHA class II (chronic) heart failure and left ventricular dysfunction (left ventricular ejection fraction ≤ 30%).
Recent Reviews